Form 4: Lilly Endowment Inc. Sells Shares of Eli Lilly & Co.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a portion of its holdings in multiple transactions on January 30, 2024.

Summary

• Lilly Endowment Inc. sold 69,370 shares of Eli Lilly & Co. common stock at a weighted average price of $645.113 per share on January 30, 2024.
• Additionally, Lilly Endowment Inc. sold 6,845 shares of Eli Lilly & Co. common stock at a weighted average price of $646.269 per share on the same day.
• The total number of shares sold was 76,215.
• Following these transactions, Lilly Endowment Inc. beneficially owns 99,412,383 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of a share sale, with no indication of positive or negative sentiment.

Industry Context

This is a routine filing related to a significant shareholder selling shares, which is a common occurrence in the market. It does not indicate any specific trend in the pharmaceutical industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and large shareholders in publicly traded companies.
• The transactions are within the normal range of trading activity for a large institutional investor like Lilly Endowment Inc.
• Comparable transactions are regularly seen in other large pharmaceutical companies such as Pfizer (PFE) and Johnson & Johnson (JNJ) when their major shareholders adjust their positions.

Stakeholder Impact

• The share sale may have a minor impact on the stock price of Eli Lilly & Co., but is unlikely to have a significant effect on other stakeholders.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, share sale, insider trading, stock transaction, beneficial ownership